Please stop back for additional upcoming events. Thank you for your interest.
Neos Therapeutics Presents Data at ASCP Annual Meeting for Investigational XR-ODT for Treatment of ADHD
Neos Therapeutics Announces Appointment of Paul Edick and John Schmid to its Board of Directors
Neos Therapeutics Announces Trade Name Cotempla XR-ODTTM for its Methylphenidate Extended-Release Orally Disintegrating Tablets
Neos Therapeutics, Inc. Appoints Thomas P. McDonnell as Chief Commercial Officer
Neos Therapeutics Completes $20.6 Million Financing to Further Advance its Late-Stage ADHD Product Pipeline
Neos Therapeutics Announces Submission of a New Drug Application for its Methylphenidate Extended Release Oral Disintegrating Tablet (XR-ODT) for the Treatment of ADHD